

(12)

(21) **2 352 874**

(51) Int. Cl. 7: **A61K 9/16, B29C 47/42**

(22) **30.11.1999**

(85) **30.05.2001**

(86) **PCT/EP99/09309**

(87) **WO00/32169**

(30) **198 55 440.0 DE 01.12.1998**

(71) **BASF AKTIENGESELLSCHAFT,  
D-67056, LUDWIGSHAFEN, XX (DE).**

**REINHOLD, ULRICH (DE).  
LANGE, ARMIN (DE).  
HOFMANN, JURGEN (DE).  
KESSLER, THOMAS (DE).  
KOTHRAD, STEPHAN (DE).**

(72) **BERNDL, GUNTHER (DE).**

(74) **ROBIC**

(54) **PROCEDE DE PRODUCTION DE FORMES DE PRESENTATION SOLIDES PAR EXTRUSION DE MASSE EN FUSION**

(54) **METHOD FOR PRODUCING SOLID FORMS OF ADMINISTRATION BY MELT EXTRUSION**

(57)

<sup>222</sup>The invention relates to a method for producing solid forms of administration <sup>2</sup>by means of melt extrusion. A polymer binder, at least one pharmaceutical <sup>2</sup>active agent and optionally, other additives are mixed and the mixture is <sup>2</sup>melted in an extruder and then extruded in the form of a continuous plastic <sup>2</sup>product strand. The inventive method is characterised in that the extruder <sup>2</sup>used is a planetary roller extruder (10) which preferably has one central <sup>2</sup>spindle (13) and six planetary spindles (14).<sup>2</sup>



(12) **DEMANDE DE BREVET CANADIEN  
CANADIAN PATENT APPLICATION**

(13) **A1**

(86) Date de dépôt PCT/PCT Filing Date: 1999/11/30  
(87) Date publication PCT/PCT Publication Date: 2000/06/08  
(85) Entrée phase nationale/National Entry: 2001/05/30  
(86) N° demande PCT/PCT Application No.: EP 99/09309  
(87) N° publication PCT/PCT Publication No.: WO 00/32169  
(30) Priorité/Priority: 1998/12/01 (198 55 440.0) DE

(51) CI.Int.<sup>7</sup>/Int.Cl.<sup>7</sup> A61K 9/16, B29C 47/42

(71) Demandeur/Applicant:  
BASF AKTIENGESELLSCHAFT, DE

(72) Inventeurs/Inventors:  
REINHOLD, ULRICH, DE;  
HOFMANN, JURGEN, DE;  
LANGE, ARMIN, DE;  
KESSLER, THOMAS, DE;  
KOTHRAD, STEPHAN, DE;  
BERNDL, GUNTHER, DE

(74) Agent: ROBIC

(54) Titre : PROCÉDE DE PRODUCTION DE FORMES DE PRESENTATION SOLIDES PAR EXTRUSION DE MASSE  
EN FUSION

(54) Title: METHOD FOR PRODUCING SOLID FORMS OF ADMINISTRATION BY MELT EXTRUSION

(57) Abrégé/Abstract:

The invention relates to a method for producing solid forms of administration by means of melt extrusion. A polymer binder, at least one pharmaceutical active agent and optionally, other additives are mixed and the mixture is melted in an extruder and then extruded in the form of a continuous plastic product strand. The inventive method is characterised in that the extruder used is a planetary roller extruder (10) which preferably has one central spindle (13) and six planetary spindles (14).



**PCT**  
WELTORGANISATION FÜR GEISTIGES EIGENTUM  
Internationales Büro  
INTERNATIONALE ANMELDUNG VERÖFFENTLICHT NACH DEM VERTRAG ÜBER DIE  
INTERNATIONALE ZUSAMMENARBEIT AUF DEM GEBIET DES PATENTWESENS (PCT)

<p>(51) Internationale Patentklassifikation <sup>7</sup> : <b>A61K 9/16</b></p>	<b>A2</b>	<p>(11) Internationale Veröffentlichungsnummer: <b>WO 00/32169</b></p> <p>(43) Internationales Veröffentlichungsdatum: <b>8. Juni 2000 (08.06.00)</b></p>
<p>(21) Internationales Aktenzeichen: <b>PCT/EP99/09309</b></p> <p>(22) Internationales Anmeldedatum: <b>30. November 1999 (30.11.99)</b></p> <p>(30) Prioritätsdaten: <b>198 55 440.0      1. Dezember 1998 (01.12.98)      DE</b></p> <p>(71) Anmelder (für alle Bestimmungsstaaten ausser US): <b>BASF AKTIENGESELLSCHAFT [DE/DE]; D-67056 Ludwigshafen (DE).</b></p> <p>(72) Erfinder; und (75) Erfinder/Anmelder (nur für US): <b>BERNDL, Gunther [DE/DE]; Am Dörrling 7, D-67273 Herxheim (DE). KOTTRADE, Stephan [DE/DE]; Albert-Einstein-Allee 17a, D-67117 Limburgerhof (DE). KESSLER, Thomas [DE/DE]; Mutterstadter Strasse 113, D-67105 Schifferstadt (DE). LANGE, Armin [DE/DE]; Furtwänglerstrasse 7, D-69121 Heidelberg (DE). HOFMANN, Jürgen [DE/DE]; Münchbuschweg 30c, D-67069 Ludwigshafen (DE). REINHOLD, Ulrich [DE/DE]; Hilgardstrasse 18, D-67346 Speyer (DE).</b></p> <p>(74) Anwälte: <b>KINZEBACH, Werner usw.; Reitschötter, Kinzebach &amp; Partner, Sternwartstr. 4, D-81679 München (DE).</b></p>	<p>(81) Bestimmungsstaaten: <b>CA, JP, US, europäisches Patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).</b></p> <p>Veröffentlicht <i>Ohne internationalen Recherchenbericht und erneut zu veröffentlichen nach Erhalt des Berichts.</i></p>	
<p>(54) Title: <b>METHOD FOR PRODUCING SOLID FORMS OF ADMINISTRATION BY MELT EXTRUSION</b></p> <p>(54) Bezeichnung: <b>VERFAHREN ZUM HERSTELLEN FESTER DARREICHUNGSFORMEN MITTELS SCHMELZEXTRUSION</b></p> <p>(57) Abstract</p> <p>The invention relates to a method for producing solid forms of administration by means of melt extrusion. A polymer binder, at least one pharmaceutical active agent and optionally, other additives are mixed and the mixture is melted in an extruder and then extruded in the form of a continuous plastic product strand. The inventive method is characterised in that the extruder used is a planetary roller extruder (10) which preferably has one central spindle (13) and six planetary spindles (14).</p> <p>(57) Zusammenfassung</p> <p>Die vorliegende Erfindung betrifft ein Verfahren zum Herstellen von festen Darreichungsformen mittels Schmelzextrusion. Dabei mischt man ein polymeres Bindemittel, wenigstens einen pharmazeutischen Wirkstoff und gegebenenfalls weitere Additive, schmelzt das Gemisch in einem Extruder auf und extrudiert es anschließend in Form eines kontinuierlichen, plastischen Produktstranges. Das erfindungsgemäße Verfahren ist dadurch gekennzeichnet, daß man als Extruder einen Planetwalzenextruder (10) verwendet, der bevorzugt eine Zentralspindel (13) und sechs Planetenspindeln (14) aufweist.</p>		

WO 00/32169

PCT/EP99/09309

## Method for Producing Solid Forms of Administration by Melt Extrusion

The present invention relates to a method for producing solid forms of administration by melt extrusion.

5 In contrast to conventional tableting methods, which are based on compacting powders or granules, in melt extrusion a melt of a polymer of thermoplastic material, which is water-soluble or capable of swelling in water and contains active ingredients, is processed. Methods for producing tablets and other forms of  
10 administration by means of melt extrusion are known, for example, from EP-A 0 240 904, EP-A 0 240 906, EP-A 0 337 256, US-A 4,880,585 and EP-A 0 358 105.

There, an extrudable pharmaceutical mixture is created by mixing and melting a polymeric binder agent, at least one active  
15 pharmaceutical ingredient and possibly further additives. An extruder is customarily employed for mixing and melting. However, the individual components can also be mixed prior to their introduction into the extruder. The melt containing active ingredients is pressed out through one or several extrusion dies,  
20 for example slot dies in the extruder head, in the form of product strings or tapes. Then the still ductile product strings or tapes are shaped into tablets or other forms of administration, such as suppositories or granules, with the aid of suitable tools. For  
25 example, the extruded melt can be compressed into shapes complementary to the desired form of administration by means of a calendaring method with counter-rotating shaping rollers. To this end, depressions complementary to the shape of the desired tablet or suppository are provided in one or both shaping rollers. In accordance with another known variation, a tape, which has

WO 00/32169

PCT/EP99/09309

depressions or openings in the desired tablet or suppository shape, is passed between smooth calendering rollers.

Single- or twin-screw extruders are customarily employed as extruders. A method for producing solid pharmaceutical  
5 dispersions is described in European Patent EP-B 0 580 860, in which a twin-screw extruder having kneading disks is employed. The employment of multi-screw extruders in the course of the production of pharmaceutical compositions is mentioned in European Patent Application EP-A 0 729 748. But actually this document  
10 only deals with twin-screw extruders with kneading disks. Extruders with more than two screws are not described either in EP-B 0 580 860 or in EP-A 0 729 748.

However, such twin-screw extruders have the disadvantage that spot-like occurring temperature peaks and large shear  
15 stresses act on the material to be plasticized in the area of the kneading disks. This poses a problem, particularly for the extrusion of melts containing active ingredients, since many active ingredients are extremely sensitive to heat. Moreover, only those polymeric binders and additives which are insensitive  
20 to increased temperatures and high shear stresses can be used in conventional twin-screw extruders with kneading disks. These disadvantages greatly limit the range of substances which are customarily employed in tablet making by means of melt extrusion.

It is therefore the object of the present invention to  
25 provide a method for producing solid forms of administration by means of melt extrusion, which makes it possible to plasticize the original substances of the extrudable mixture, i.e. the polymeric binders and the active pharmaceutical compositions in particular, in a gentle manner, in particular without the appearance of high  
30 shear and temperature stresses, and to mix them.

WO 00/32169

PCT/EP99/09309

This object is attained by the method in accordance with the attached main claim. In accordance with the invention, for the production of solid forms of administration by means of melt extrusion it is proposed to mix a polymeric binder, at least one  
5 active pharmaceutical composition, and possibly further additives in a planetary roller extruder, to melt them and to subsequently extrude them in the shape of a continuous ductile production string.

Surprisingly it was found that, when employing a planetary  
10 roller extruder, it is possible to also work sensitive polymers, materials and additives into a solid form of administration.

Planetary roller extruders are known per se and for example are produced in Germany by Entex Rust & Mitschke GmbH of Bochum.

Planetary roller extruders are continuous screw kneaders,  
15 whose kneading element is embodied in the manner of a planetary rolling mill. The same as conventional single- and twin-screw extruders, planetary roller extruders also have a material inlet, which is followed by a plastification and homogenization zone. A cooling zone for cooling the heated material mixture to the  
20 extrusion temperature is customarily arranged upstream of the outlet nozzle. The plastification and homogenization zone has a central spindle, which typically is notched at less than 45°. Several planetary spindles mesh with this central spindle and, in turn, engage a cylindrical bushing with teeth on the interior.  
25 When the central spindle is driven, the planetary spindles freely rotate in a rolling-off process between the bushing and the central spindle. They are not seated and swim in the material to be extruded during the operation. To the extent that the teeth are in engagement with the central spindle, or the interior teeth  
30 of the bushing, each planetary spindle represents a sort of a

WO 00/32169

PCT/EP99/09309

propeller pump. The material to be plasticized is typically pushed axially into the plastification and homogenization zone of the planetary roller extruder and is very extensively rolled out between the rotating planetary spindles and the central spindle, on the one hand, or the bushing with interior teeth on the other hand.

The material to be plasticized which reaches the gap clearance between the teeth is repeatedly subjected to a short term spot-shaped rolling stress but, because of the roll-off movement of the planetary spindles on the central spindle, is immediately relaxed again and released. The material absorbs the required plastification heat in a very short time because of this thin film rolling and is intensely mixed and kneaded and homogenized in the process.

Planetary roller extruders are customarily of very short construction because of their considerably higher efficiency in respect to single- and twin-screw extruders, so that the dwell times of the material to be extruded in the plastification and homogenization zone are also very short.

If required, the plasticized and homogenized material is grasped by a downstream-connected short discharge screw and can be extruded through breaker plates or other nozzles. However, the extruder can also be operated without die plates and without a pressure buildup.

The plastification and homogenization zone of the extruder is customarily heatable. To this end, heating or cooling means, for example, can be conducted through the housing jacket of the extruder surrounding the bushing.

The planetary roller extruder is particularly advantageously constructed in a module-like manner from individual

WO 00/32169

PCT/EP99/09309

sections, wherein the layout of the rollers and the temperature profile can be separately optimized for each section.

The planetary roller extruder is distinguished by easy self-cleaning properties, which is particularly advantageous when producing pharmaceuticals.

The pressureless chambers existing between the roller units assure sufficient degassing of the material to be plasticized.

In spite of the short-term temperature and shear stresses, it is possible by means of the method of the invention to achieve the optimum homogenization of the material in the shortest time. This has shown itself to be advantageous when producing solids solutions, since it becomes possible to achieve a molecularly dispersed distribution of the active ingredient in the matrix without the use of solvents and high temperatures.

On the average, with the method of the invention, i.e. the employment of a planetary roller extruder, the temperatures needed for plasticizing and homogenizing the pharmaceutical mixture are approximately 20°C lower than the temperatures required by the conventional extrusion methods, i.e. when using a twin-screw extruder.

A planetary roller extruder having a central spindle and three to eight planetary spindles is advantageously used.

The use of a planetary roller extruder having six planetary spindles is particularly preferred. It is possible by means of this arrangement to mix and plasticize the mixture to be extruded particularly effectively without excessive temperature and shear stresses of the material occurring.

The planetary roller extruder does not require kneading disks because of the good intermixing and plastification of the pharmaceutical mixture. The above described disadvantages



WO 00/32169

PCT/EP99/09309

occurring, for example, when twin-screw extruders with kneading disks are employed, are avoided with the method in accordance with the invention.

5 The dwell time of the pharmaceutical mixture in the planetary roller extruder is short and preferably is approximately 0.5 to 2 minutes, depending on the number of revolutions of the central spindle and the length of the roller element.

10 Since in accordance with the method of the invention the material to be plasticized is not subjected to temperature and shear stresses lasting over a long time, a planetary roller extruder is particularly suitable for extruding materials which contain heat- or shear-sensitive substances, which can be active material, excipients or added materials here.

15 Therefore the use of a planetary roller extruder for extruding a heat-sensitive pharmaceutical mixture is also an object of the invention.

20 Within the scope of the present invention, the term "form of administration" should be understood in its broadest possible sense. It is tied neither to any definite shape nor to a definite application. It therefore includes, for example, tablets for peroral application, suppositories for rectal application, granules, or even larger shapes, such as cubes, blocks (cuboids) or cylindrical shapes. The method in accordance with the invention is suitable for producing any arbitrary forms of  
25 administration, which are finding use, for example, as medicaments, plant treatment agents, feeds and foodstuffs, as well as for the release of scents and essential oils.

30 All materials having a pharmaceutical effect and the least possible side effects are understood to be active pharmaceutical agents, provided that they do not decompose under the processing

WO 00/32169

PCT/EP99/09309

conditions. The amounts of effective agent per unit of dosage and the concentration can vary within wide limits, depending on their effectiveness and speed of release. The only condition here is that they are sufficient for obtaining the desired effects. The concentration of active agents in respect to the total weight of the form of administration therefore can lie in the range between 0 and 90, preferably between 0.1 and 60. In the present connection, the term active ingredient also includes any arbitrary combinations of active ingredients. For example, vitamins are also active ingredients in the sense of the invention. Preferred active ingredients are ibuprofen (in the form of racemates, enantiomers or enriched enantiomers), ketoprofen, flurbiprofen, acetylsalicylic acid, verpamil, paracetamol, nifedipin and catopril.

But the method in accordance with the invention is particularly suitable for heat-sensitive substances such as, for example, enzymes, peptides, vitamins, hormones, insulin, plant extracts, dihydropyridine derivatives, antibiotics, for example makrolyte or zytostatic agents. The method in accordance with the invention is also particularly suited for the extrusion of plant extracts and other natural active ingredients.

The method in accordance with the invention is particularly suited for producing solid forms of administration containing those polymers which, because of their high molecular weight or thermolability, are subject to decomposition phenomena in the course of extrusion in twin-screw extruders, for example oxidative degradation, depolymerization, molecular weight loss, elimination of side groups, or which enter into chemical reactions with other components of the formulation.

In the total mixture of all components, the polymeric

WO 00/32169

PCT/EP99/09309

5 binder must soften or melt in the range between 50 and 250°C, preferably 60 to 180°C, and particularly preferred in the range between 80 to 150°C. Therefore the glass transition temperature of the mixture must lie below 200°C, preferably below 150°C, and particularly preferred below 130°C. If required, it will be reduced by conventional, pharmacologically acceptable plasticizing excipients. Suitable polymeric binders are described in WO 97/15291, for example.

10 The following are preferably employed as polymeric binders for the melt extrusion of active pharmaceutical agents: polymers or copolymers of N-vinyl pyrrolidone, eudragit types (acrylic resins) or celluloses. Particularly preferred here are: polyvinyl pyrrolidone (PVP), copolymers of N-vinyl pyrrolidone and vinyl esters, such as vinyl acetate, poly(hydroxyalkylacrylates),  
15 poly(hydroxyalkylmethacrylates), polyacrylates, polymethacrylates, alkyl celluloses or hydroxyalkyl celluloses.

Besides the polymeric binder and the active ingredient(s), the extrudable mixture can also contain customary additives, for example plasticizers, lubricants, solvents, dyestuffs,  
20 stabilizers, or wetting, preservative, blasting, adsorption, unmolding and expanding agents. Also, customary galenic excipients, for example extenders or fillers, can be contained in it. Suitable additives and galenic excipients are described in WO 97/15291, for example.

25 The typical structure of a planetary roller extruder is shown in a sectional representation in the attached drawing.

Following its plastification and homogenization area, the planetary roller extruder 10 has a heatable, essentially  
30 cylindrical housing jacket 11, on whose interior wall a bushing 12 is arranged, out of whose interior surface a helical groove 12a

WO 00/32169

PCT/EP99/09309

has been cut. A driveable central spindle 13 is rotatably seated centered in the interior of the bushing 12 and is surrounded by several freely rotating planetary spindles 14. Each planetary spindle 14 meshes with its helical outer surface 14a with the helical outer surface 13a of the central spindle 13, as well as with the interior spiral 12a of the bushing 12. The bushing 12 is arranged, fixed against relative rotation, in the housing of the planetary roller extruder 10. A thrust ring, not visible in the sectional representation of the attached drawing figure, for the rotating planetary spindles 14 is arranged at the extruder end.

#### Example 1:

Production of a Solids Solution of Ibuprofen in a Matrix of Kollidon 90 F, Using a Planetary Roller Extruder

30 wt.-% of ibuprofen were extruded together with 69.5 wt.-% of Kollidon 90 F of a k value of 90, and with 0.5 wt.-% of Aerosil 200 in a planetary roller extruder.

The planetary roller extruder had a central spindle of a diameter of 43 mm, which was surrounded by six planetary spindles each of a diameter of 20 mm and of a length of 398 mm each. Extrusion was performed at a number of revolutions of 40 rpm and with a throughput of 5kg/h.

Plasticizing and homogenizing took place at a maximum temperature in the extruder of 150°C.

Following extrusion, the k value of Kollidon was 85.

Comparison Example 1:

WO 00/32169

PCT/EP99/09309

Production of a Solids Solution of Ibuprofen in a Matrix of  
Kollidon 90 F, Using a Twin-Screw Extruder

30 wt.-% of ibuprofen were extruded together with 69.5 wt.-%  
of Kollidon 90 F of a k value of 90, and with 0.5 wt.-% of  
Aerosil 200 in a ZSK twin-screw extruder of the Werner &  
Pfleiderer company at a number of revolutions of 100 rpm and a  
throughput of 2 kg/h.

A maximum temperature in the extruder of 190°C was required  
for satisfactory plasticizing and homogenizing.

Following extrusion, the k value of Kollidon was only  
approximately 70.

WO 00/32169

PCT/EP99/09309

## Claims

1. A method for producing solid forms of administration by melt extrusion, wherein a polymeric binder, at least one active pharmaceutical agent and, if required, further additives are mixed in an extruder and melted, and are subsequently extruded in a continuous ductile production string, characterized in that a planetary roller extruder (10) is used as the extruder.

2. The method in accordance with claim 1, characterized in that a planetary roller extruder (10) with a central spindle (13) and three to eight planetary spindles (14) are used.


3. The method in accordance with claim 2, characterized in that a planetary roller extruder (10) with six planetary spindles (14) is used.

4. The method in accordance with one of claims 1 to 3, characterized in that a planetary roller extruder (10) without kneading disks is used.

5. The method in accordance with one of claims 2 to 4, characterized in that the number of revolutions of the central spindle (14) of the planetary roller extruder (10) is set in such a way that the dwell time in the extruder (10) of a pharmaceutical mixture to be extruded is approximately 0.5 to 2 minutes.

6. Use of a planetary roller extruder for extruding a heat- and/or shear-sensitive pharmaceutical mixture.

1 / 1

**Fig.**